SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Edgewise Therapeutics to Participate in Upcoming Investor Conferences Edgewise Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireBOULDER, Colo., Nov. 9, 2026 BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage...

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3...

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results Edgewise Therapeutics Reports Third Quarter 2026 Financial ResultsPR NewswireBOULDER, Colo., Nov. 4, 2026 Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain Phase 3 trial for...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Nov. 2, 2026 BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400PR NewswireBOULDER, Colo., Oct. 8, 2026 Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at...

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Oct. 1, 2026BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireBOULDER, Colo., Sept. 22, 2026 - TheMoA that...

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? 

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten.</li><li>Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy.</li><li>The transaction is expected to close in the third quarter of 2026.</li></ul>Shares of Edgewise Therapeutics (EWTX) soared more than 20% on Monday, climbing to record high, after French drugmaker Servier unveiled a multibillion-dollar deal to acquire the company’s muscular dystrophy business.<a href="https://stocktwits.com/symbol/EWTX">EWTX shares</a> could clock their biggest single-day gains in more than six months if the stock closes at current levels.<h2 class="st-heading-2">EWTX To Receive $1.55B Upfront</h2>On Monday, Servier expanded its footprint in rare neuromuscular disorders through a $2.65 billion deal to acquire Edgewise Therapeutics’ muscular dystrophy business, including programs targeting Becker and Duchenne muscular dystrophies.Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones. The transaction is expected to close in the third quarter of 2026.<h2 class="st-heading-2">EWTX’s Sevasemten In Spotlight</h2>The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten. The investigational oral therapy is designed to protect fragile muscles from contraction-related damage in patients with rare muscular dystrophies.Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy (BMD) and a Phase 2 study for Duchenne muscular dystrophy (DMD). There are currently no approved treatments for BMD, a rare genetic disorder that causes progressive muscle weakness and loss of function.“This transaction is designed to place the program in the hands of an organization with the experience and infrastructure to support its continued development for people living with Becker and Duchenne muscular dystrophies,” said Kevin Koch, CEO of Edgewise Therapeutics.<h2 class="st-heading-2">Sevasemten Shows Strong Safety Profile</h2>Edgewise’s MESA extension study is currently evaluating the long-term safety and effectiveness of Sevasemten in patients with Becker muscular dystrophy.According to data presented at the 2026 MDA Clinical and Scientific Conference in March, patients maintained stable physical function for up to 3.5 years, compared with the decline typically seen in the disease. The drug also demonstrated a favorable cardiac safety profile over 12 months, with signs of improved cardiac function in some patients.<h2 class="st-heading-2">EWTX Sentiment Remains Bullish</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.One user noted that upon completion of the deal, Edgewise will become a cardiovascular-focused company.<stembedurl>https://stocktwits.com/G101SPM/message/654951591</stembedurl>The stock has gained around 30% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-glsi-stock-rising-today-form-10k-delay-update-breast-cancer-trial/cZ0gpnyReH0">GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones.

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$47.33
Prev Close	$45.04
Open	$46.02
Dividend Yield	0.00%
50-Day Moving Average	$40.85
Beta	1.35
Avg. Volume	1.38M
PE Ratio	5.50

52-Week High	$48.51
52-Week Low	$16.98
Market Capitalization	$4.93B
EPS (Annual)	-$1.63
Price to Book	3.02
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

EWTX Fundamentals